Cargando…

Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination

Vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy in preventing the onset of disease. However, the immune response to infection immediately after the first vaccination remains unknown. We examined the anti-SARS-CoV-2-binding-antibody titers and neutra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okumura, Nobumasa, Saito, Sho, Takamatsu, Yuki, Takeuchi, Junko S., Asai, Yusuke, Sanada, Mio, Iwamoto, Noriko, Maeda, Kenji, Mitsuya, Hiroaki, Ohmagari, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444155/ https://www.ncbi.nlm.nih.gov/pubmed/36067912 http://dx.doi.org/10.1016/j.jiac.2022.08.026

Ejemplares similares

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants
por: Tsuchiya, Kiyoto, et al.
Publicado: (2023)

Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
por: Inada, Makoto, et al.
Publicado: (2023)

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
por: Terada, Mari, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan
por: Shoji, Kensuke, et al.
Publicado: (2022)

Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis
por: Shoji, Kensuke, et al.
Publicado: (2023)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Temporal trends in microbial detection during the COVID-19 pandemic: Analysis of the Japan surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) database
por: Endo, Akira, et al.
Publicado: (2023)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study
por: Yamamoto, Shohei, et al.
Publicado: (2021)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
por: Inada, Makoto, et al.
Publicado: (2021)

Does the SARS-CoV-2 rapid antigen test result correlate with the viral culture result?
por: Yamamoto, Kei, et al.
Publicado: (2021)

Time-course evaluation of the quantitative antigen test for severe acute respiratory syndrome coronavirus 2: The potential contribution to alleviating isolation of COVID-19 patients
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study
por: Yano, Rina, et al.
Publicado: (2023)

An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
por: Tomita, Noriko, et al.
Publicado: (2023)

Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
por: Kutsuna, Satoshi, et al.
Publicado: (2021)

Treatment with tecovirimat of the first two cases of monkeypox in Japan
por: Inada, Makoto, et al.
Publicado: (2023)

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
por: Inada, Makoto, et al.
Publicado: (2022)

Predictors of silent hypoxia in hospitalized patients with COVID-19 in Japan
por: Hayakawa, Kayoko, et al.
Publicado: (2022)

Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan
por: Suzuki, Tetsuya, et al.
Publicado: (2022)

Considerations and concerns regarding the readiness to remove face coverings
por: Terada, Mari, et al.
Publicado: (2022)

Varicella pneumonia in an immunocompetent, unvaccinated man: A case report
por: Okumura, Nobumasa, et al.
Publicado: (2021)

Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study
por: Tomita, Noriko, et al.
Publicado: (2023)

Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test
por: Suzuki, Michiyo, et al.
Publicado: (2023)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers()
por: Suzuki, Tetsuya, et al.
Publicado: (2021)

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study
por: Takeuchi, Junko S., et al.
Publicado: (2022)

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan
por: Tanaka, Akihito, et al.
Publicado: (2021)

Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron
por: Adachi, Eisuke, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period
por: Shoji, Kensuke, et al.
Publicado: (2022)

First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics
por: Saito, Sho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f6l69bo1pb5pmirlpbtn95mr31